Opinion|Videos|October 4, 2024

Clinical Pearls about the Referral Process of Bispecifics and CAR-T in RRMM

Author(s)Samer A. Al'Hadidi, MD, Frits van Rhee, MD, PhD, Appalanaidu Sasapu, MD

The discussion shares key takeaways and practical insights for optimizing the referral and treatment process for CAR T-cell and bispecific therapies.

Episodes in this series

EP. 1 Importance of Collaboration between Academic and Community Centers

EP. 1 Importance of Collaboration between Academic and Community Centers

EP. 2 Referral Process: Streamlining and Challenges Seen

EP. 2 Referral Process: Streamlining and Challenges Seen

EP. 3 Referral Process: Bispecifics

EP. 3 Referral Process: Bispecifics

EP. 4 Similarities and Differences among Bispecifics: BCMA vs non-BCMA

EP. 4 Similarities and Differences among Bispecifics: BCMA vs non-BCMA

EP. 5 Types of Referrals and Impact of Social Factors on the Referral Process

EP. 5 Types of Referrals and Impact of Social Factors on the Referral Process

EP. 6 Managing AEs Seen with Bispecifics

EP. 6 Managing AEs Seen with Bispecifics

EP. 7 Referral Process: CAR T-Cell Therapy

EP. 7 Referral Process: CAR T-Cell Therapy

EP. 8 CAR T: Impact of Recent Approvals on the Referral Process

EP. 8 CAR T: Impact of Recent Approvals on the Referral Process

EP. 9 Long-Term Monitoring of AEs and Reintegrating Patients back into Community Care

EP. 9 Long-Term Monitoring of AEs and Reintegrating Patients back into Community Care

EP. 10 Clinical Pearls about the Referral Process of Bispecifics and CAR-T in RRMM

EP. 10 Clinical Pearls about the Referral Process of Bispecifics and CAR-T in RRMM

Video content above is prompted by the following:

Please share some key takeaways/pearls.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Rheumatoid arthritis RA in an autoimmune disease faultry activated b cells emitting antibodies which attack the joints causes inflammation front view 3d illustration. with copy space image | Image Credit © vxnaghiyev - stock.adobe.com

September 23rd, 2026

Optimizing Cilta-Cel Sequencing and Community Coordination in Multiple Myeloma

Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.

Trending on CancerNetwork

Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications

Acting on a HER2 Result and Navigating Access to Therapy

The Case for Frontline Zongertinib in HER2-Mutant NSCLC

Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC

Patient-Centered Treatment Transitions in HR+/HER2− mBC